-

Eurofins and Rite Aid Launch an Over-the-Counter, FDA-Authorised, at-Home COVID-19 PCR Test in all Rite Aid Locations in the U.S.

LUXEMBOURG--(BUSINESS WIRE)--Eurofins (Paris:ERF), through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit. The co-branded kits, available at all Rite Aid stores across 17 states in the USA, will offer customers a convenient way to test for the virus from their home and will detect the virus in symptomatic and asymptomatic patients.

The at-home COVID-19 nasal PCR kit is among the first over-the-counter at-home test kits for SARS-CoV-2 to receive US Food and Drug Administration Emergency Use Authorization (EUA). The test was developed by Eurofins Viracor, a leading infectious disease testing laboratory, and is based on its FDA EUA authorised SARS-CoV-2 RT-PCR assay. As of December 2020, this later assay offers one of the best sensitivity rates of 117 laboratories that have submitted results to the FDA’s SARS-CoV-2 Reference Panel; https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data#results.

Eurofins’ CEO, Gilles Martin commented: "We are excited to partner with Rite Aid and launch this at-home COVID-19 testing kit, making access to test kits widely available to people across the U.S through Rite Aid’s national network. Increasing population testing rates is an important step in fighting the pandemic, and its new more infectious variants, and building the confidence needed to accelerate a return to everyday life.”

[1]This home-collection kit has not been FDA cleared or approved; rather it has been authorised by FDA under an EUA only for the home collection and maintenance of nasal swab specimens as an aid in detection of nucleic acid from SARS-CoV-2, and not for any other viruses or pathogens, and only for the duration of the declaration that circumstances exist justifying the authorisation of emergency use of medical devices under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.Eurofins Shares are listed on Euronext Paris Stock Exchange.

About empowerDX
empowerDX is the online shop for easy at-home health testing. empowerDX specializes in FDA-authorized COVID-19 testing, women’s health, men’s health, sexual health and general wellness testing.

Contacts

Annemarie Watson
ir@eurofins.com

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

Annemarie Watson
ir@eurofins.com

More News From Eurofins Scientific

Eurofins: Weekly Report on Share Repurchases From 20th July to 24th July 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 20/07/2026 FR0014000MR3 3 180 70.8332 CEUX EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 20/07/2026 FR0014000MR3 6 820 70.7743 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 21/07/...

Eurofins Makes Significant Progress in H1 2026 Towards Its Mid-Term 2027 Objectives, With 130bps of Adjusted EBITDA Margin Expansion, Strong Cash Conversion, and 29% EPS Growth

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Financial highlights in H1 2026 Basic EPS8 grew 29% to €1.55 in H1 2026 vs €1.20 in H1 2025, as Eurofins continued to accumulate the operational benefits from the five-year investment programme in its hub and spoke network of laboratories and digitalisation initiatives. Revenues of €3,701m increased by 2.5% as reported including a 2.9% headwind from foreign currency, and 2.7% organically13. Organic growth13 improved as the half...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 13th July to 17th July 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Weekly report on share repurchases from 13th July to 17th July 2026   Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/07/2026 FR0014000MR3 15 000 69.1984 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/07...
Back to Newsroom